{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T06:19:15Z","timestamp":1787552355371,"version":"build-2736575974"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"\n Background<\/jats:title>\n \n Helicobacter pylori<\/jats:italic>\n infects approximately 4. 4 billion individuals worldwide, causing chronic gastritis, peptic ulcer disease, and gastric adenocarcinoma. The 2024 ACG guideline recommends bismuth-based quadruple therapy (BQT) as first-line treatment when susceptibility is unknown, while vonoprazan\u2013amoxicillin (VA) dual therapy is conditionally endorsed as an alternative. Prior meta-analyses included vonoprazan-containing BQT control arms, introducing heterogeneity that may influence comparative efficacy estimates. This analysis addresses that gap by restricting the comparator to conventional PPI-based BQT.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n A systematic search of PubMed\/MEDLINE, EMBASE, Web of Science, CINAHL, Google Scholar, and the Cochrane Library was conducted through April 2026 (PROSPERO: CRD420251108849) for randomized controlled trials (RCTs). All comparator arms were restricted to conventional PPI-based BQT. Outcomes included eradication rate, total adverse events (AE), nausea, diarrhea, treatment compliance, and bitter taste. Certainty of evidence was assessed using the GRADE approach and trial sequential analysis. Meta-analysis was performed using R software.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n From 17,661 screened articles, 15 RCTs comprising 4,410 patients were included. Pooled eradication rates were 86.4% with VA and 85.0% with BQT, with no statistically significant difference (RR 1.03, 95% CI 1.00\u20131.07;\n p<\/jats:italic>\n = 0.05;\n I<\/jats:italic>\n 2<\/jats:sup>\n = 46.1%). VA significantly reduced total AEs (17.1% vs. 35.4%; RR 0.48, 95% CI 0.42\u20130.54;\n p<\/jats:italic>\n &lt; 0.01;\n I<\/jats:italic>\n 2<\/jats:sup>\n = 0.0%), nausea (4.4% vs. 10.6%; RR 0.44, 95% CI 0.32\u20130.59;\n p<\/jats:italic>\n &lt; 0.01;\n I<\/jats:italic>\n 2<\/jats:sup>\n = 26.7%), and bitter taste (5.6% vs. 14.5%; RR 0.10, 95% CI 0.06\u20130.18;\n p<\/jats:italic>\n &lt; 0.01;\n I<\/jats:italic>\n 2<\/jats:sup>\n = 43.2%). No significant differences were observed for diarrhea or compliance. GRADE certainty was moderate for eradication, low for AEs, nausea, and bitter taste, and very low to low for diarrhea and compliance. Trial sequential analysis confirmed sufficient evidence for reductions in AEs, nausea, and bitter taste, while eradication, diarrhea, and compliance remained inconclusive.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n VA dual therapy achieves eradication rates comparable to PPI-based BQT while offering a significantly more favorable tolerability profile, driven by fewer total AEs, less nausea, and less bitter taste. As all included trials were conducted in China, generalizability requires further investigation. These findings support VA dual therapy as a viable alternative for first-line\n H. pylori<\/jats:italic>\n management.\n <\/jats:p>\n \n Systematic review registration:<\/jats:bold>\n https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?RecordID=1108849<\/jats:ext-link>\n , identifier: CRD420251108849.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fmicb.2026.1872669","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T05:27:52Z","timestamp":1787549272000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative efficacy and safety of vonoprazan-based dual therapy vs. bismuth-based quadruple therapy for Helicobacter pylori eradication: a GRADE-assessed systematic review and meta-analysis with trial sequential analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Alejandro","family":"Chen Liang","sequence":"first","affiliation":[{"name":"Centro de Estudios Universitarios Xochicalco","place":["Campus Tijuana, Tijuana, M\u00e9xico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeison","family":"Cruz Castillo","sequence":"additional","affiliation":[{"name":"Universidad Aut\u00f3noma de Santo Domingo","place":["Santo Domingo, Rep\u00fablica Dominicana"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena M.","family":"Murrieta Bruciaga","sequence":"additional","affiliation":[{"name":"Universidad del Valle de M\u00e9xico","place":["Hermosillo, M\u00e9xico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Abreu Lopez","sequence":"additional","affiliation":[{"name":"Maimonides Medical Center","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma Beltr\u00e1n","family":"Covarrubias","sequence":"additional","affiliation":[{"name":"Universidad de Guadalajara","place":["Guadalajara, M\u00e9xico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector Jonan","family":"Flores Uribe","sequence":"additional","affiliation":[{"name":"Centro de Estudios Universitarios Xochicalco","place":["Campus Tijuana, Tijuana, M\u00e9xico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa Pamela","family":"Salolin-Vargas","sequence":"additional","affiliation":[{"name":"Facultad de Medicina","place":["Universidad Westhill, Ciudad de M\u00e9xico, M\u00e9xico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Flores Monar","sequence":"additional","affiliation":[{"name":"University of Miami\/Jackson Health System","place":["Miami, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Garc\u00eda-Corella","sequence":"additional","affiliation":[{"name":"Department of Medicine","place":["UCLA-Kern Medical, Bakersfield, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishaan","family":"Kalha","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology","place":["Department of Medicine, UCLA-Kern Medical, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Calderon Martinez","sequence":"additional","affiliation":[{"name":"Texas Tech University Health Sciences Center El Paso","place":["El Paso, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1080\/08998280.2025.2491964","article-title":"Vonoprazan and amoxicillin dual therapy versus bismuth-based therapy for Helicobacter pylori eradication: a systematic review and meta-analysis of randomized controlled trials","volume":"38","author":"Abosheaishaa","year":"2025","journal-title":"Baylor Univ. Med. Center Proc."},{"key":"B2","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3949\/ccjm.91a.24031","article-title":"Helicobacter pylori: a concise review of the latest treatments against an old foe","volume":"91","author":"Aldhaleei","year":"2024","journal-title":"Cleve. Clin. J. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3390\/microorganisms12010222","article-title":"Helicobacter pylori: a contemporary perspective on pathogenesis, diagnosis and treatment strategies","volume":"12","author":"Ali","year":"2024","journal-title":"Microorganisms"},{"key":"B4","unstructured":"Computer Vision Assisted Data Extraction from Charts Using WebPlotDigitizer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"747027","DOI":"10.1155\/2023\/9747027","article-title":"Overview of Helicobacter pylori infection, prevalence, risk factors, and its prevention","volume":"2023","author":"Bashir","year":"2023","journal-title":"Adv. Gut Microbiome Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1733070","DOI":"10.3389\/fmicb.2025.1733070","article-title":"Commentary: Efficacy and safety of vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for patients with Helicobacter pylori infection: a meta-analysis","volume":"16","author":"Chen Liang","year":"2025","journal-title":"Front. Microbiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12876-024-03225-8","article-title":"Comparison of vonoprazan dual therapy, quadruple therapy and standard quadruple therapy for Helicobacter pylori infection in Hainan: a single-center, open-label, non-inferiority, randomized controlled trial","volume":"24","author":"Chen","year":"2024","journal-title":"BMC Gastroenterol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/jgh.70179","article-title":"Randomized comparison of vonoprazan\u2013amoxicillin dual therapy versus bismuth quadruple therapies for Helicobacter pylori eradication: a multicenter trial evaluating national centralized drug procurement antibiotics","volume":"41","author":"Cheng","year":"2026","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e13133","DOI":"10.1111\/hel.13133","article-title":"Vonoprazan dual or triple therapy versus bismuth-quadruple therapy as first-line therapy for Helicobacter pylori infection: a three-arm, randomized clinical trial","volume":"29","author":"Cheung","year":"2024","journal-title":"Helicobacter"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.14309\/ajg.0000000000002968","article-title":"ACG clinical guideline: treatment of Helicobacter pylori infection","volume":"119","author":"Chey","year":"2024","journal-title":"Am. J. Gastroenterol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1053\/j.gastro.2022.05.055","article-title":"Vonoprazan triple and dual therapy for Helicobacter pylori infection in the United States and Europe: randomized clinical trial","volume":"163","author":"Chey","year":"2022","journal-title":"Gastroenterology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"990","DOI":"10.3390\/antibiotics14100990","article-title":"Comparison of vonoprazan and low-dose amoxicillin dual therapy with bismuth-containing quadruple therapy for na\u00efve Helicobacter pylori eradication: a single-center, open-label, randomized control trial","volume":"14","author":"Fan","year":"2025","journal-title":"Antibiotics"},{"key":"B13","unstructured":"Streamline Evidence-Based Guidelines with GRADEpro"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e12970","DOI":"10.1111\/hel.12970","article-title":"Eradication rates of Helicobacter pylori in treatment-naive patients following 14-day vonoprazan-amoxicillin dual therapy: a multicenter randomized controlled trial in China","volume":"28","author":"Hu","year":"2023","journal-title":"Helicobacter"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.3748\/wjg.v30.i27.3304","article-title":"Vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication in Chinese population: a prospective, multicenter, randomized, two-stage study","volume":"30","author":"Huang","year":"2024","journal-title":"World J. Gastroenterol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/apt.13121","article-title":"Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects","volume":"41","author":"Jenkins","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"118185","DOI":"10.1016\/j.biopha.2025.118185","article-title":"Restoration of intestinal barrier function by fexuprazan, a potassium-competitive acid blocker, in Caco-2 cells and its higher gastrointestinal distribution in rats","volume":"188","author":"Jeon","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1080\/00365521.2024.2407898","article-title":"Eradication rate and safety of vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication: a randomized controlled trial","volume":"59","author":"Jiang","year":"2024","journal-title":"Scand. J. Gastroenterol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s40360-026-01147-7","article-title":"Comparison of the anti-inflammatory effects of esomeprazole and fexuprazan in lipopolysaccharide-stimulated RAW 264.7 macrophages","volume":"27","author":"Ju","year":"2026","journal-title":"BMC Pharmacol. Toxicol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/gastroent16030035","article-title":"A novel approach to H. pylori eradication: a narrative review of vonoprazan-based therapies","volume":"16","author":"Kornatowska","year":"2025","journal-title":"Gastroenterol. Insights"},{"key":"B21","doi-asserted-by":"publisher","first-page":"118386","DOI":"10.1016\/j.biopha.2025.118386","article-title":"Fexuprazan mitigates NSAID-induced small intestinal injury by restoring intestinal barrier integrity in mice","volume":"190","author":"Lee","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"B22","doi-asserted-by":"publisher","first-page":"5637","DOI":"10.2147\/IDR.S417711","article-title":"Modified 14-day dual therapy with vonoprazan and amoxicillin amplified the advantages over conventional therapies for eradication of Helicobacter pylori: a non-inferiority clinical trial","volume":"16","author":"Li","year":"2023","journal-title":"Infect. Drug Resist."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1561749","DOI":"10.3389\/fmicb.2025.1561749","article-title":"Efficacy and safety of vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for patients with Helicobacter pylori infection: a meta-analysis","volume":"16","author":"Li","year":"2025","journal-title":"Front. Microbiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1580969","DOI":"10.3389\/fphar.2025.1580969","article-title":"Clinical pharmacokinetics of potassium competitive acid blockers: a systematic review and meta-analysis","volume":"16","author":"Liu","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5056\/jnm18139","article-title":"Role of acid suppression in acid-related diseases: proton pump inhibitor and potassium-competitive acid blocker","volume":"25","author":"Mori","year":"2019","journal-title":"J. Neurogastroenterol. Motil."},{"key":"B26","unstructured":"PROSPERO"},{"key":"B27","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B28","doi-asserted-by":"publisher","first-page":"4011","DOI":"10.1007\/s10238-023-01074-5","article-title":"Combination of vonoprazan and amoxicillin as the first-line Helicobacter pylori eradication therapy: a multicenter, prospective, randomized, parallel-controlled study","volume":"23","author":"Peng","year":"2023","journal-title":"Clin. Exp. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"627","DOI":"10.14309\/ajg.0000000000002086","article-title":"Ten-day vonoprazan-amoxicillin dual therapy as a first-line treatment of Helicobacter pylori infection compared with bismuth-containing quadruple therapy","volume":"118","author":"Qian","year":"2023","journal-title":"Am. J. Gastroenterol."},{"key":"B30","unstructured":"The R Project fo R Statistical Computing"},{"key":"B31","unstructured":"AI-Powered Systematic Review Management Platform"},{"key":"B32","unstructured":""},{"key":"B33","unstructured":"Current Version of RoB 2"},{"key":"B34","unstructured":"Posit"},{"key":"B35","unstructured":"Sch\u00fcnemann\n H.\n \n \n Bro\u017cek\n J.\n \n \n Guyatt\n G.\n \n \n Oxman\n A.\n \n \n GRADE Handbook"},{"key":"B36","doi-asserted-by":"publisher","first-page":"25","DOI":"10.5056\/jnm.2013.19.1.25","article-title":"Pharmacokinetics and pharmacodynamics of the proton pump inhibitors","volume":"19","author":"Shin","year":"2013","journal-title":"J. Neurogastroenterol. Motil."},{"key":"B37","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.kjms.2016.04.009","article-title":"Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori","volume":"32","author":"Shinozaki","year":"2016","journal-title":"Kaohsiung J. Med. Sci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s40265-023-01991-5","article-title":"Vonoprazan: a review in Helicobacter pylori infection","volume":"84","author":"Shirley","year":"2024","journal-title":"Drugs"},{"key":"B39","unstructured":"Home Page"},{"key":"B40","doi-asserted-by":"publisher","first-page":"645","DOI":"10.3390\/antibiotics9100645","article-title":"Effect of antibiotic susceptibility and CYP3A4\/5 and CYP2C19 genotype on the outcome of vonoprazan-containing Helicobacter pylori eradication therapy","volume":"9","author":"Sugimoto","year":"2020","journal-title":"Antibiotics"},{"key":"B41","first-page":"1","article-title":"User Manual for Trial Sequential Analysis (TSA)","author":"Thorlund","year":"2011"},{"key":"B42","doi-asserted-by":"publisher","first-page":"17562848231190976","DOI":"10.1177\/17562848231190976","article-title":"Efficacy and safety of vonoprazan-amoxicillin dual therapy for Helicobacter pylori first-line treatment: a single-center, randomized, controlled trial","volume":"16","author":"Wang","year":"2023","journal-title":"Ther. Adv. Gastroenterol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"655","DOI":"10.14309\/ajg.0000000000002592","article-title":"Ten-day vonoprazan-amoxicillin dual therapy vs standard 14-day bismuth-based quadruple therapy for first-line Helicobacter pylori eradication: a multicenter randomized clinical trial","volume":"119","author":"Yan","year":"2024","journal-title":"Am. J. Gastroenterol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"E35610","DOI":"10.1097\/MD.0000000000035610","article-title":"A randomized clinical study on the efficacy of vonoprazan combined with amoxicillin duo regimen for the eradication of Helicobacter pylori","volume":"102","author":"Yang","year":"2023","journal-title":"Medicine"},{"key":"B45","doi-asserted-by":"publisher","first-page":"70070","DOI":"10.1002\/ueg2.70070","article-title":"Efficacy and safety of vonoprazan and high-dose amoxicillin dual therapy for rescue treatment of Helicobacter pylori infection: a multicenter randomized controlled trial","volume":"13","author":"Zhang","year":"","journal-title":"United Euro. Gastroenterol. J."},{"key":"B46","doi-asserted-by":"publisher","first-page":"17562848251354868","DOI":"10.1177\/17562848251354868","article-title":"Fourteen-day vonoprazan-amoxicillin dual therapy versus 14-day bismuth-based quadruple therapy for Helicobacter pylori treatment: a randomized clinical trial","volume":"18","author":"Zhang","year":"","journal-title":"Ther. Adv. Gastroenterol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"102768","DOI":"10.1016\/j.jiph.2025.102768","article-title":"The efficacy and safety of vonoprazan-based high-dose dual therapy for eradication of Helicobacter pylori: a systematic review and meta-analysis","volume":"18","author":"Zhang","year":"","journal-title":"J. Infect. Public Health"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e13040","DOI":"10.1111\/hel.13040","article-title":"Vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: a systematic review and meta-analysis","volume":"29","author":"Zhou","year":"2024","journal-title":"Helicobacter"}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1872669\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T05:27:53Z","timestamp":1787549273000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1872669\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":48,"alternative-id":["10.3389\/fmicb.2026.1872669"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2026.1872669","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"article-number":"1872669"}}